Sofosbuvir for treatment of chronic hepatitis C
Chronic hepatitis C is a leading cause of liver-related morbidity and mortality worldwide. If untreated, chronic hepatitis C can progress to advanced liver fibrosis, cirrhosis, liver failure, hepatocellular carcinoma and death. Until recently, treatment of hepatitis C predominantly constituted an im...
Gespeichert in:
| Veröffentlicht in: | Hepatology international 2015-04, Vol.9 (2), p.161-173 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 173 |
|---|---|
| container_issue | 2 |
| container_start_page | 161 |
| container_title | Hepatology international |
| container_volume | 9 |
| creator | Kattakuzhy, Sarah Levy, Rachel Kottilil, Shyam |
| description | Chronic hepatitis C is a leading cause of liver-related morbidity and mortality worldwide. If untreated, chronic hepatitis C can progress to advanced liver fibrosis, cirrhosis, liver failure, hepatocellular carcinoma and death. Until recently, treatment of hepatitis C predominantly constituted an immunomodulatory agent, peg-interferon-alfa and ribavirin. In 2011, the first class of directly acting antiviral agents, HCV NS3/4A serine protease inhibitors, was added to peg-interferon-alfa and ribavirin with increased efficacy. In the past year, an NS5B inhibitor, sofosbuvir, has emerged as a potent agent with pangenotypic efficacy, resulting in the first interferon-free regimen for the treatment of hepatitis C. This review summarizes the data that resulted in regulatory approval of sofosbuvir and highlights the future of hepatitis C therapy with sofosbuvir as the backbone of a highly effective antiviral regimen. |
| doi_str_mv | 10.1007/s12072-014-9606-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1687667022</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1671209476</sourcerecordid><originalsourceid>FETCH-LOGICAL-c541t-b9f5b60fa6c920cf8a7557f6c13883d97bacabe6e00dfb8c86761b34f8ec43973</originalsourceid><addsrcrecordid>eNqNkE1LAzEQhoMotlZ_gBdZ8OJl7WSz-TpK8QsKHtRzyKaJ3dLd1GRX8N-bsrWIIHiagXnmHeZB6BzDNQbg04gL4EUOuMwlA5bLAzTGkrAcaIkP9z0hI3QS4wqAUobZMRoVlAuBZTlG02fvfKz6jzpkzoesC1Z3jW27zLvMLINva5Mt7UZ3dVfHbHaKjpxeR3u2qxP0enf7MnvI50_3j7ObeW7S6S6vpKMVA6eZkQUYJzSnlDtmMBGCLCSvtNGVZRZg4SphBOMMV6R0wpqSSE4m6GrI3QT_3tvYqaaOxq7XurW-jwozwRnjUBT_QHnyJEvOEnr5C135PrTpkS0FIAoiaaLwQJngYwzWqU2oGx0-FQa1Fa8G8SqJV1vxSqadi11yXzV2sd_4Np2AYgBiGrVvNvw4_WfqFwtfi9I</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1670082395</pqid></control><display><type>article</type><title>Sofosbuvir for treatment of chronic hepatitis C</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Kattakuzhy, Sarah ; Levy, Rachel ; Kottilil, Shyam</creator><creatorcontrib>Kattakuzhy, Sarah ; Levy, Rachel ; Kottilil, Shyam</creatorcontrib><description>Chronic hepatitis C is a leading cause of liver-related morbidity and mortality worldwide. If untreated, chronic hepatitis C can progress to advanced liver fibrosis, cirrhosis, liver failure, hepatocellular carcinoma and death. Until recently, treatment of hepatitis C predominantly constituted an immunomodulatory agent, peg-interferon-alfa and ribavirin. In 2011, the first class of directly acting antiviral agents, HCV NS3/4A serine protease inhibitors, was added to peg-interferon-alfa and ribavirin with increased efficacy. In the past year, an NS5B inhibitor, sofosbuvir, has emerged as a potent agent with pangenotypic efficacy, resulting in the first interferon-free regimen for the treatment of hepatitis C. This review summarizes the data that resulted in regulatory approval of sofosbuvir and highlights the future of hepatitis C therapy with sofosbuvir as the backbone of a highly effective antiviral regimen.</description><identifier>ISSN: 1936-0533</identifier><identifier>EISSN: 1936-0541</identifier><identifier>DOI: 10.1007/s12072-014-9606-9</identifier><identifier>PMID: 25788194</identifier><language>eng</language><publisher>India: Springer India</publisher><subject>Antiviral Agents - therapeutic use ; Clinical Trials as Topic ; Colorectal Surgery ; Hepacivirus - genetics ; Hepatitis C ; Hepatitis C virus ; Hepatitis C, Chronic - drug therapy ; Hepatology ; Humans ; Medicine ; Medicine & Public Health ; Review Article ; Sofosbuvir - therapeutic use ; Surgery</subject><ispartof>Hepatology international, 2015-04, Vol.9 (2), p.161-173</ispartof><rights>Asian Pacific Association for the Study of the Liver 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c541t-b9f5b60fa6c920cf8a7557f6c13883d97bacabe6e00dfb8c86761b34f8ec43973</citedby><cites>FETCH-LOGICAL-c541t-b9f5b60fa6c920cf8a7557f6c13883d97bacabe6e00dfb8c86761b34f8ec43973</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12072-014-9606-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12072-014-9606-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25788194$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kattakuzhy, Sarah</creatorcontrib><creatorcontrib>Levy, Rachel</creatorcontrib><creatorcontrib>Kottilil, Shyam</creatorcontrib><title>Sofosbuvir for treatment of chronic hepatitis C</title><title>Hepatology international</title><addtitle>Hepatol Int</addtitle><addtitle>Hepatol Int</addtitle><description>Chronic hepatitis C is a leading cause of liver-related morbidity and mortality worldwide. If untreated, chronic hepatitis C can progress to advanced liver fibrosis, cirrhosis, liver failure, hepatocellular carcinoma and death. Until recently, treatment of hepatitis C predominantly constituted an immunomodulatory agent, peg-interferon-alfa and ribavirin. In 2011, the first class of directly acting antiviral agents, HCV NS3/4A serine protease inhibitors, was added to peg-interferon-alfa and ribavirin with increased efficacy. In the past year, an NS5B inhibitor, sofosbuvir, has emerged as a potent agent with pangenotypic efficacy, resulting in the first interferon-free regimen for the treatment of hepatitis C. This review summarizes the data that resulted in regulatory approval of sofosbuvir and highlights the future of hepatitis C therapy with sofosbuvir as the backbone of a highly effective antiviral regimen.</description><subject>Antiviral Agents - therapeutic use</subject><subject>Clinical Trials as Topic</subject><subject>Colorectal Surgery</subject><subject>Hepacivirus - genetics</subject><subject>Hepatitis C</subject><subject>Hepatitis C virus</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Hepatology</subject><subject>Humans</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Review Article</subject><subject>Sofosbuvir - therapeutic use</subject><subject>Surgery</subject><issn>1936-0533</issn><issn>1936-0541</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqNkE1LAzEQhoMotlZ_gBdZ8OJl7WSz-TpK8QsKHtRzyKaJ3dLd1GRX8N-bsrWIIHiagXnmHeZB6BzDNQbg04gL4EUOuMwlA5bLAzTGkrAcaIkP9z0hI3QS4wqAUobZMRoVlAuBZTlG02fvfKz6jzpkzoesC1Z3jW27zLvMLINva5Mt7UZ3dVfHbHaKjpxeR3u2qxP0enf7MnvI50_3j7ObeW7S6S6vpKMVA6eZkQUYJzSnlDtmMBGCLCSvtNGVZRZg4SphBOMMV6R0wpqSSE4m6GrI3QT_3tvYqaaOxq7XurW-jwozwRnjUBT_QHnyJEvOEnr5C135PrTpkS0FIAoiaaLwQJngYwzWqU2oGx0-FQa1Fa8G8SqJV1vxSqadi11yXzV2sd_4Np2AYgBiGrVvNvw4_WfqFwtfi9I</recordid><startdate>20150401</startdate><enddate>20150401</enddate><creator>Kattakuzhy, Sarah</creator><creator>Levy, Rachel</creator><creator>Kottilil, Shyam</creator><general>Springer India</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7U7</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>7U9</scope><scope>H94</scope></search><sort><creationdate>20150401</creationdate><title>Sofosbuvir for treatment of chronic hepatitis C</title><author>Kattakuzhy, Sarah ; Levy, Rachel ; Kottilil, Shyam</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c541t-b9f5b60fa6c920cf8a7557f6c13883d97bacabe6e00dfb8c86761b34f8ec43973</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Antiviral Agents - therapeutic use</topic><topic>Clinical Trials as Topic</topic><topic>Colorectal Surgery</topic><topic>Hepacivirus - genetics</topic><topic>Hepatitis C</topic><topic>Hepatitis C virus</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Hepatology</topic><topic>Humans</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Review Article</topic><topic>Sofosbuvir - therapeutic use</topic><topic>Surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kattakuzhy, Sarah</creatorcontrib><creatorcontrib>Levy, Rachel</creatorcontrib><creatorcontrib>Kottilil, Shyam</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Toxicology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Hepatology international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kattakuzhy, Sarah</au><au>Levy, Rachel</au><au>Kottilil, Shyam</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sofosbuvir for treatment of chronic hepatitis C</atitle><jtitle>Hepatology international</jtitle><stitle>Hepatol Int</stitle><addtitle>Hepatol Int</addtitle><date>2015-04-01</date><risdate>2015</risdate><volume>9</volume><issue>2</issue><spage>161</spage><epage>173</epage><pages>161-173</pages><issn>1936-0533</issn><eissn>1936-0541</eissn><abstract>Chronic hepatitis C is a leading cause of liver-related morbidity and mortality worldwide. If untreated, chronic hepatitis C can progress to advanced liver fibrosis, cirrhosis, liver failure, hepatocellular carcinoma and death. Until recently, treatment of hepatitis C predominantly constituted an immunomodulatory agent, peg-interferon-alfa and ribavirin. In 2011, the first class of directly acting antiviral agents, HCV NS3/4A serine protease inhibitors, was added to peg-interferon-alfa and ribavirin with increased efficacy. In the past year, an NS5B inhibitor, sofosbuvir, has emerged as a potent agent with pangenotypic efficacy, resulting in the first interferon-free regimen for the treatment of hepatitis C. This review summarizes the data that resulted in regulatory approval of sofosbuvir and highlights the future of hepatitis C therapy with sofosbuvir as the backbone of a highly effective antiviral regimen.</abstract><cop>India</cop><pub>Springer India</pub><pmid>25788194</pmid><doi>10.1007/s12072-014-9606-9</doi><tpages>13</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1936-0533 |
| ispartof | Hepatology international, 2015-04, Vol.9 (2), p.161-173 |
| issn | 1936-0533 1936-0541 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1687667022 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Antiviral Agents - therapeutic use Clinical Trials as Topic Colorectal Surgery Hepacivirus - genetics Hepatitis C Hepatitis C virus Hepatitis C, Chronic - drug therapy Hepatology Humans Medicine Medicine & Public Health Review Article Sofosbuvir - therapeutic use Surgery |
| title | Sofosbuvir for treatment of chronic hepatitis C |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T05%3A47%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sofosbuvir%20for%20treatment%20of%20chronic%20hepatitis%20C&rft.jtitle=Hepatology%20international&rft.au=Kattakuzhy,%20Sarah&rft.date=2015-04-01&rft.volume=9&rft.issue=2&rft.spage=161&rft.epage=173&rft.pages=161-173&rft.issn=1936-0533&rft.eissn=1936-0541&rft_id=info:doi/10.1007/s12072-014-9606-9&rft_dat=%3Cproquest_cross%3E1671209476%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1670082395&rft_id=info:pmid/25788194&rfr_iscdi=true |